Top of this page
Skip navigation, go straight to the content
Overview investors
Uniting our strengths with our investors' to deliver superior, long-term shareholder value
Our Investor Relations team strives to offer a first class service to UCB's current shareholders, potential investors and the financial investment community as a whole.
UCB has the potential to become the next generation biopharma leader
- Powerful and unique combination of biology and chemistry research capabilities
- 12 large and small molecules in clinical development, spanning 16 different types of diseases
- A track record of turning novel ideas into therapeutic and commercial realities
- Solid product life-cycle management
Contact our IR team
Quick access IR
News List ›
- Neupro® recommended for approval in Europe for Restless Legs Syndrome 25-April-2008
- UCB's CEO Confirms Company Strategy 24-April-2008
- Cimzia® Approved in the US for the Treatment of Moderate to Severe Crohn's Disease 22-April-2008
- Phase II results for CDP791 in non-small cell lung cancer support further clinical development 31-March-2008
Upcoming Events
| Date | Event details |
|---|---|
|
15 May 2008 |
Interim update (Q1, 2008) |
|
01 August 2008 |
Half-Year 2008 Financial Results |
